Initiation of a Phase 2 Multicenter Study of 18F-APN-1607, a Novel Diagnostic PET Imaging Tracer for the Characterization of Tau Burden in Alzheimer’s Disease
TAIPEI, Nov. 21, 2019 /PRNewswire/ -- APRINOIA Therapeutics, Inc. announced today that it has initiated a Phase 2 multicenter, multinational...